German Pharmaceutical company BioNTech said on Monday it aimed to start trialling a malaria vaccine by next year, using the same breakthrough mRNA technology at the core of Covid-19 vaccines to help fight the mosquito-borne disease, which kills more than 400,000 people every year.
